NCT03647800 - Study of APVO436 in Patients With AML or MDS | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

December 15, 2022

Study Completion Date

June 15, 2023

Conditions

AMLMDS

Interventions

BIOLOGICAL

APVO436

Trial Locations (12)

14263

ACTIVE_NOT_RECRUITING

Roswell Park Cancer Institute, Buffalo

29605

RECRUITING

Greenville Health System, Institute for Translational Oncology Research, Greenville

32610

RECRUITING

University of Florida College of Medicine, Gainesville

33136

RECRUITING

Sylvester Comprehensive Cancer Center/UMHC, Miami

43210

RECRUITING

The Ohio State University Wexner Medical Center/James Cancer Hospital, Columbus

66205

RECRUITING

The University of Kansas Clinical Research Center, Westwood

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

77030

RECRUITING

The University of Texas M.D. Anderson Cancer Center, Houston

80218

RECRUITING

Colorado Blood Cancer Institute, Denver

84112

RECRUITING

University of Utah, Huntsman Cancer Institute, Salt Lake City

94143

ACTIVE_NOT_RECRUITING

University of California, San Francisco Medical Center, San Francisco

98109

ACTIVE_NOT_RECRUITING

Fred Hutchinson Cancer Research Center, Seattle